Company intelligence / Profile preview

Engrail Therapeutics

San Diego, California, USAengrail.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Engrail has reported positive results from a phase 1b trial of ENX‑101 in healthy volunteers showing favorable safety and pharmacokinetics. The company has initiated a phase 2 trial for ENX‑102 in generalized anxiety disorder and started a phase 1 study for ENX‑104 targeting anhedonic major depressive disorder. Their pipeline includes six unique programs spanning multiple CNS indications.

Therapeutic areas: DermatologyPsychiatryNeurologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

ENX-102

5 more assets in the full pipeline.

Request access →

Partnerships

Pivotal Life Sciences (founding investor/supporter)No specific pharma co-development partners disclosed as of May 2025 but strong VC syndicate partnerships

Beyond the preview

Go deeper on Engrail Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engrail Therapeutics.

Explore the full profile